# Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

> **NCT06998056** · PHASE2 · COMPLETED · sponsor: **Arcutis Biotherapeutics, Inc.** · enrollment: 101 (actual)

## Conditions studied

- Atopic Dermatitis (Eczema)

## Interventions

- **DRUG:** ARQ-151 cream 0.05%

## Key facts

- **NCT ID:** NCT06998056
- **Lead sponsor:** Arcutis Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-09
- **Primary completion:** 2025-12-04
- **Final completion:** 2025-12-04
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06998056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06998056, "Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06998056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*